Artemis Therapeutics Inc.
ATMS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $56 | $56 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $56 | $56 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -14.6% | 19.1% | 49.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.9% | 93.7% | 83.2% | 75% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -86.9% | -132.5% | -150.3% | -422.4% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 0% | 7.3% | -135.3% | -446.6% |
| EPS Diluted | 0 | 0 | -0.002 | -0.091 |
| % Growth | -100% | 100% | 97.7% | – |
| Operating Cash Flow | – | – | -$0 | -$0 |
| Capital Expenditures | – | – | $0 | -$0 |
| Free Cash Flow | – | – | -$0 | -$0 |